ElsaLys Biotech
France-based developer of therapeutic monoclonal antibodies.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD14—21m (Dealroom.co estimates May 2013.)
Masovian Voivodeship Poland (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | 1.1m | 1.1m |
| % growth | (60 %) | 1981 % | (98 %) | 10271 % | (2 %) | 54 % | - |
| EBITDA | (3.7m) | (4.2m) | (3.6m) | (5.1m) | (4.2m) | - | - |
| % EBITDA margin | (18953 %) | (1045 %) | (51229 %) | (702 %) | (588 %) | - | - |
| Profit | (3.6m) | (4.1m) | (3.8m) | (3.6m) | (4.8m) | - | - |
| % profit margin | (18918 %) | (1018 %) | (54329 %) | (497 %) | (668 %) | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Grant | ||
€2.1m | Series A | ||
€325k | Grant | ||
€270k | Grant | ||
| Total Funding | AUD4.6m | ||
Related Content
Recent News about ElsaLys Biotech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.